CZO.V - Ceapro Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.54
-0.01 (-1.82%)
At close: 3:18PM EST
Stock chart is not supported by your current browser
Previous Close0.55
Open0.56
Bid0.57 x 0
Ask0.58 x 0
Day's Range0.52 - 0.56
52 Week Range0.49 - 1.75
Volume65,337
Avg. Volume101,364
Market Cap40.909M
Beta4.52
PE Ratio (TTM)49.09
EPS (TTM)0.01
Earnings DateNov 21, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Marketwired23 days ago

    Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice C.M. Jones ...

  • Marketwiredlast month

    Ceapro to Present at Noble Capital Markets' 14th Annual Investor Conference

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., ...

  • Marketwired2 months ago

    Ceapro Announces Grant of Stock Options and Restricted Share Units

    Ceapro Inc. today announced the granting of stock options and restricted share units to employees and officers of the Company.

  • Marketwired3 months ago

    Ceapro Reports 2017 Third Quarter Business Update and Financial Results

    Ceapro Inc. a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for ...

  • Marketwired4 months ago

    Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE

    - Successful execution of Juvente Inc. acquisition marks an important step in Ceapro's strategic market diversification business plan -

  • Ceapro, Inc. :CZO-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017
    Capital Cube6 months ago

    Ceapro, Inc. :CZO-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017

    Categories: Yahoo FinanceGet free summary analysis Ceapro, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Ceapro, Inc. – ProMetic Life Sciences Inc., GeneNews Limited and Medicure Inc. (PLI-CA, GEN-CA and MPH-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD ... Read more (Read more...)

  • Marketwired6 months ago

    Ceapro Reports 2017 Second Quarter Business Update and Financial Results

    Ceapro Inc. a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for ...

  • Ceapro, Inc. :CZO-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
    Capital Cube7 months ago

    Ceapro, Inc. :CZO-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017

    Categories: Yahoo FinanceGet free summary analysis Ceapro, Inc. reports financial results for the quarter ended March 31, 2017. Highlights Summary numbers: Revenues of CAD 3.18 million, Net Earnings of CAD 0.02 million. Gross margins narrowed from 68.80% to 52.60% compared to the same period last year, operating (EBITDA) margins now 11.33% from 51.73%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research8 months ago

    CZO In-line 4Q:17 Revenues; PGX Advancing

    On May 17, 2017, Ceapro Inc. (CZO.V) posted financial and operational results and filed interim statements for the first quarter of 2017.  Revenues during the period were $3.2 million and matched our estimates.  Due to lower gross margin and higher operating expenses, earnings of $18 thousand or $0.00 per share fell below our predictions of $0.9 million or $0.01 per share.  These results compare to first quarter 2016 revenues of $4.1 million and per share earnings of $0.02.

  • Marketwired9 months ago

    Ceapro Announces Results of 2017 Shareholders' Meeting

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, ...

  • Marketwired9 months ago

    Ceapro Inc. Announces its First Major Milestones with its PGX Enabling Technology

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided an update of the Company's ...

  • Marketwired9 months ago

    Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., ...

  • Marketwired9 months ago

    Ceapro Inc. Reports 2017 First Quarter Development Highlights and Financial Results

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for ...

  • Zacks Small Cap Research9 months ago

    CZO.V: CoQ10 and Beta Glucan in Energy Drink

    Ceapro Inc. (CZO.V) announced the successful combination of beta glucan (BG) and coenzyme Q10 (CoQ10) using its PGX technology in a May 4, 2017 press release.  CoQ10 is a fat soluble antioxidant that helps convert food into energy and and may have wide ranging health benefits including the reduction of oxidative stress and heart heatlh.  The company additionally announced the completion of the first development stage of this project which consisted of two studies related to the combination of beta glucan and CoQ10 and the testing of a functional beverage. The tests demonstrated the ability of the PGX technology to form stable mixtures of CoQ10 in water from impregnation of the coenzyme onto a highly porous surface such as BG.  The BG, in turn, acts as a carrier to improve the bioavailability CoQ10 to transport it to the mitochondria of the cells where it is able to impart its antioxidant and energy conversion characteristics.  While widely available as a nutritional supplement, CoQ10 in its commercially available form has poor bioavailability due to its low aqueous solubility and high molecular weight.  The combination with BG through the use of PGX serves to address this shortcoming.

  • Marketwired10 months ago

    Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion ...

  • Zacks Small Cap Research10 months ago

    CZO.V: Focus Shifts to Development Programs

    On April 6, 2017, Ceapro Inc. (CZO.V) released full-year 2016 financial and operational results.  2016 revenues of $13.7 million rose 28% over the prior year and earnings of 5.1c posted a near 50% increase on an adjusted basis.   These results are below our estimates of $14.7 million in revenues and earnings of 6.2c (note that all currency herein is denominated in Canadian dollars). By geography, on a year over year basis, 2016 sales increases in the US, Canada, Germany and Other were offset by declines in China.  In the fourth quarter, sales fell 29% vs. Q4:15 as Germany and China did not maintain previous year sales’ levels.  The 4Q:16 vs. 4Q:15 difference was also attributable to a significant reduction in orders for beta glucan.   Sequentially, Ceapro experienced quarterly declines in US, Germany, and Canada but increases in China and Other regions.

  • Marketwired11 months ago

    Ceapro Inc. Reports 2016 Financial Results and Provides Corporate Update

    Ceapro Inc. , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for ...

  • Accesswire11 months ago

    Research Reports Initiated on Healthcare Stocks Medifocus, Ceapro, and Crescita Therapeutics

    LONDON, UK / ACCESSWIRE / April 6, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...